Issue link: https://viewer.e-digitaledition.com/i/695025
SCIENCE SNPs WHITE MATTER MATTERS A new study published in the journal Neuron reports a previously unrecognized characteristic in the brains of people with Down syndrome: a defect in production of white matter. White matter in the brain is important for proper communication between neurons and overall brain function. The white matter is made mostly of the substance myelin, which in turn is produced by a specific type of brain cells, oligodendrocytes. While studying brains of deceased individuals of various ages as well as Down syndrome mouse models, the investigators discovered a defect in the function of oligodendrocytes and the production of myelin. Importantly, this defect is observed mostly after birth, indicating that early therapeutic interventions could rescue white matter formation. Future research will be aimed at identifying the mechanism by which trisomy 21 leads to less white matter, a necessary step to identify drugs or other therapeutic strategies to improve white matter production and enhance brain function. Neuron, MARCH 2016 GOOD NEWS FROM DENMARK A team of international scientists led by Sonja Rasmussen,M.D., M.S., at the Centers for Disease Control and Prevention analyzed data from 3,530people with trisomy 21 (the clinical name for Down syndrome) culled from the 1968 Danish Cytogenetic Register, and produced the latest and most comprehensive analysis of cancer incidence in people with Down syndrome. Since this population has seen remarkable increase in life expectancy, and because cancer is most frequent in older people, it was important to define cancer incidence in older individuals with trisomy 21. Unlike previous studies, which included few older individuals, the new study includes a large number of participants over age 50. The results confirm a much lower incidence of solid tumors across all ages, especially in older individuals, with the exception of testicular cancer. For example, only three cases of CONTINUED FROM PAGE 9 Kelly Sullivan, Ph.D., Instructor in the Department of Pharmacology at CU Anschutz Medical Campus, will study the impact of regulating or adjusting the activity of interferons, molecules with potent effects on the immune system, in people with Down syndrome. BEST IN CLASS "The Crnic Institute is the only academic home in the United States focused on research and medical care benefitting people with Down syndrome," said Joaquín Espinosa, Ph.D., Associate Director for Science at the Crnic Institute. "Our grant program is truly the best in the nation, and this year's recipients have the potential to reveal novel strategies that could lead to therapies or improve the health outcomes of people with Down syndrome in our lifetime." The additional 2016 Crnic Grand Challenge Grants were awarded to six outstanding researchers: Ganna Bilousova, Ph.D., Assistant Professor in the Department of Dermatology at CU Anschutz Medical Campus, will focus on defects in endothelial progenitor cells in people with Down syndrome. These cells help rebuild the lining inside blood vessels, and the research may explain why people with Down syndrome are more likely to develop heart defects and Alzheimer's disease. Mike Klymkowsky, Ph.D., Professor at CU Boulder, will analyze neuronal development in people with Down syndrome using human-induced pluripotent stem cells and cerebral organoids, structures produced in a lab that resemble the developing fetal brain. Changwei Liu, Ph.D., Assistant Professor in the Department of Biochemistry and Molecular Genetics at CU Anschutz Medical Campus, will focus on the ubiquitin proteasome pathway — defects in which contribute to the development of numerous diseases — and the role it plays in Down syndrome. Will Old, Ph.D., Assistant Professor at CU Boulder, will study how the DYRK1A gene found on chromosome 21 influences neurodevelopment. His research could lead to targeted therapies to improve cognition and learning. Chad Pearson, Ph.D., Assistant Professor in the Department of Cell and Developmental Biology at CU Anschutz Medical Campus will examine cilia, small structures found on many cells, which are known to be deregulated in other genetic conditions and which seem to play a role in Down syndrome. Rui Yi, Ph.D., Associate Professor at CU Boulder, will explore the molecular mechanisms by which the miR-155 gene found on chromosome 21 may lead to the development of leukemia in people with Down syndrome. For more information about the Crnic Institute and Global's commitment to funding progress in Down syndrome research, visit globaldownsyndrome.org. SPRING2016 DOWN SYNDROME WORLD 10

